Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Ling Felce

MBiochem, DPhil

In Memoriam: 1986-2022

In 2020 I joined NDM to work in Professor Tao Dong's and Professor Julian Knight's groups. My current focus is on characterising T cell responses against different SARS-CoV-2 epitopes through the use of integrated single cell RNA sequencing and TCR repertoire analysis. This can be linked with experimental functional assays, allowing us to fully understand epitope-specific T cell phenotypes across different COVID-19 severities and over the course of SARS-CoV-2 infection.

I previously undertook postdoctoral positions first with Professor Alison Banham (NDCLS/RDM) in understanding the role of transcription factor FOXP1 in immune evasion in diffuse large B cell lymphoma, and subsequently with Dr Gillian Farnie (NDORMS), where I investigated the epigenetic effects of MLLT1, a histone reader, in breast cancer and acute myeloid leukaemia. 

Prior to my postdoctoral work, I graduated from University of Oxford with a degree in Molecular and Cellular Biochemistry (MBiochem), focusing in my master's year on immunology, virology and oncology. I completed my DPhil in Clinical Pharmacology from the Department of Oncology, University of Oxford, working on the design, production and testing of B-cell targeting cancer vaccines based on different viral vectors. My DPhil was funded by a Medical Research Council Studentship.